A Phase 3 Study of Volrustomig Versus Observation in People with Inoperable Head and Neck Cancer That Has Not Grown After Chemoradiotherapy

Full Title

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) (WCG IRB)

Purpose

Researchers want to see how well volrustomig works to treat people with inoperable head and neck squamous cell cancer (HNSCC). Inoperable means the cancer cannot be taken out with surgery. The people in this study have HNSCC that has not grown after chemotherapy and radiation given at the same time.

If you take part in this study, you will be randomly assigned to get either:

• Volrustomig, which is given intravenously (by vein).
• Observation, which means you will be monitored and not receive volrustomig.

Who Can Join

To join this study, there are a few conditions. You must:

• Have stage 3-4 HNSCC and just completed concurrent chemotherapy and radiation therapy.
• Be age 18 or older.

 

Contact

For more information about this study or to see if you can join, please call Dr. Eric Sherman’s office at 646-608-3776.